mRNA vaccine plus immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new mRNA vaccine that targets a unique part of your tumor cells, given together with an immunotherapy drug (anti-PD-1). It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of advanced or metastatic solid tumor (like pancreatic, breast, lung, melanoma, or colorectal cancer) that has not been controlled by standard treatments.
- A sample of your tumor (from a biopsy or surgery) must show a specific genetic marker (circFAM53B-219aa) and you must have a certain immune type (HLA) that matches the vaccine.
- You should be able to do your daily activities with minimal help (ECOG score 0-2) and be expected to live at least 3 more months.
- Your blood counts, liver, kidney, heart, and lung function need to be within specific ranges.
- You cannot have an active infection, autoimmune disease, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This study tests a new mRNA vaccine that targets a protein called FAP, which is found in many solid tumors. It is for people whose cancer has not responded to or cannot tolerate standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.